Roche Partners with Chai Discovery to Deploy Chai-3 Across Global Therapeutic Pipelines
Article excerpt
Highlighted: the sentence this signal was extracted from
Founded in 2024 by Joshua Meier, Jack Dent, Matthew McPartlon, and Jacques Boitreaud - with founding team experience spanning OpenAI, Meta Fundamental AI Research (FAIR), Stripe, and academic molecular design - Chai Discovery positions its technology stack as a modern computer-aided design (CAD) suite for biological therapeutics. Rather than merely predicting static folded conformations from existing primary sequences, Chai's generative models reason over biological structure, chemical topology, and dynamic protein function to engineer novel molecular binders from scratch. The collaboration with Roche is anchored by Chai-3, the company's latest multi-modal foundation model, which demonstrates high target hit rates and nanomolar-range binding affinities. The system is specifically optimized for complex target geometries where conventional wet-lab structural assays struggle to identify druggable binding sites. Backing this technological development is an investor syndicate that includes Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Oak HC/FT, General Catalyst, OpenAI, Thrive Capital, and Menlo Ventures. The collaboration between Roche and Chai Discovery illustrates three fundamental transformations shaping computational biology, pharmaceutical licensing, and enterprise AI commercialization. First, the industry is transitioning from predictive folding to...
Keep reading with a free account
The rest of this article, and every signal for Roche, is in your free account.
